ANTI-CTLA-4 TREATMENT PROMOTE THE EXPANSION OF CD39+ CONVENTIONAL CD4+ T CELLS

ABRATE, CAROLINA; ACOSTA RODRIGUEZ E V; BOSSIO, SABRINA N.; GRUPPI, ADRIANA; RODRIGUEZ, CONSTANZA; MONTES, CAROLINA L

Virtual

Congreso; Reunion anual SAI, SAIC, AAFE, NANOMED-AR; 2021

ANTI-CTLA-4 TREATMENT PROMOTE THE EXPANSION OF CD39+ CONVENTIONAL CD4+ T CELLSBossio S1, Abrate C1, Rodriguez C1, Gruppi A1, Acosta Rodriguez EV1, Montes CL1. 1Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, Argentina.Revista Medicina Vol 81 Supl. III-2021. Reunion de Sociedades de Biociencias SAIC-SAI-AAFE-NANOMED-ARPreviously we demonstrated that tumors from different experimental mice models are infiltrated with FOXP3- CD4+ cells (Tconv) expressing CD39. CD39 is an unequivocal marker CD8+ of exhaustion. Tumor infiltrating (TI) CD39+Tconv cells represent a heterogeneous population with features of exhaustion. Transcriptional profiling of TI-CD39+Tconv cells showed that they exhibit a transcriptional signature associated with cytotoxic CD4+ T cells. In this work, we aim to evaluate the impact of Anti-CTLA-4 treatment on TI-CD39+Tconv cells. C57BL7/6 mice were injected with 0.5x106 MC38 tumor cells. On days, 4, 7 and 10 mice were treated with anti-CTLA-4 (100ug/ mice) or IgG (Control). On day 17 we evaluated by flow cytometry the phenotype of the TI-CD39+Tconv cells. As expected, anti–CTLA- 4 treated mice exhibited reduced tumor volume and frequency of TI-Tregs respect to controls (p